Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

NCT07243626 | Recruiting Phase 2

• 1 other identifier: IR2023375
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

Soft tissue sarcoma (STS) is a rare, highly heterogeneous malignancy with a poor prognosis. The standard first-line treatment for advanced patients is anthracyclines (doxorubicin, A) combined with ifosfamide (I, AI regimen), but the efficacy is limited, and some subtypes do not respond well. Immune checkpoint inhibitors (ICI) have shown potential in specific STS subtypes. Anthracyclines can induce immunogenic cell death and upregulate PD-L1, providing a theoretical basis for combined immunotherapy. Previous studies have shown that ICI combined with chemotherapy (such as pembrolizumab + doxorubicin) is more effective than chemotherapy alone. Envolizumab is the world's first subcutaneously injected PD-L1 single-domain antibody-Fc fusion protein, with significant advantages: (1) small molecular weight (\~80kDa) and strong tissue penetration; (2) high stability and can be stored at room temperature; (3) convenient subcutaneous injection and good tolerability (Phase II study of MSI-H/dMMR solid tumors ORR 42.7%, grade 3-4 TEAE 15.5%). In 2022, the FDA granted orphan drug designation for the treatment of STS. This study aims to evaluate the efficacy (ORR, PFS, OS, etc.) and safety of Envolizumab combined with an AI regimen (doxorubicin + ifosfamide) as a first-line treatment for advanced STS.

Conditions

Soft Tissue Sarcoma

Outcome Measures

Primary Outcomes (1)

• Efficcy-Progression-free survival

  PFS

  From enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Secondary Outcomes (5)

• Efficcy-Objective response rate

  From enrollment to the end of treatment at 8 weeks

• Efficcy-Disease control rate

  From enrollment to the end of treatment at 8 weeks

• Efficcy-overall survival

  From enrollment until the date of death from any cause, assessed up to 60 months

• adverse events-safety

  From enrollment to the end of treatment at 8 weeks

• Efficacy: 1-year os rate

  From enrollment to 1 year

Study Arms (1)

intervention

EXPERIMENTAL

Eligible patients with soft tissue sarcoma were enrolled and treated with Envafolimab 300 mg/dose subcutaneously every 3 weeks on day 1. The AI regimen consisted of liposomal doxorubicin 35 mg/m² on day 1 and intravenous infusion of IFO 2.5 mg/m² on days 1-3, every 3 weeks. Efficacy and safety were assessed approximately every 6 weeks (42 ± 7 days). Patients with disease control (CR+PR+SD) and tolerable adverse reactions could choose continue treatment until disease progression, unacceptable toxicity, or discontinuation at the investigator's discretion.

Drug: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)

Interventions

Envafolimab combined with an AI regimen (doxorubicin and ifosfamide) DRUG

Envafolimab combined with an AI regimen: liposomal doxorubicin 35 mg/m² on day 1; IFO 2.5 mg/m² on days 1-3, intravenous infusion, every 3 weeks.

intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pathologically confirmed advanced soft tissue sarcoma with at least one measurable lesion.
• No previous systemic treatment.
• ≥18 years old; expected survival time more than 3 months;
• Major organ function within 7 days before treatment, meeting the following criteria:
• (1) Routine blood test criteria (without blood transfusion within 14 days):
• Hemoglobin (HB) ≥90g/L; ② Absolute neutrophil count (ANC) ≥1.5×109/L; ③ Platelet count (PLT) ≥80×109/L. (2) Biochemical examinations must meet the following criteria: ① Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); ② Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2.5 ULN. If liver metastasis is present, ALT and AST ≤ 5 ULN; ③ Serum creatinine (Cr) ≤ 1.5 ULN or creatinine clearance (CCr) ≥ 60ml/min; (3) Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%). 5. Women of childbearing age must agree to use contraceptive measures (such as intrauterine devices, birth control pills or condoms) during the study and within 6 months after the study; serum or urine pregnancy tests must be negative within 7 days before study enrollment, and the patients must not be breastfeeding; men must agree to use contraceptive measures during the study and within 6 months after the study.

You may not qualify if:

• Chondrosarcoma (CS), osteosarcoma (OS), Ewing's sarcoma, dermatofibrosarcoma protuberans (DFSP), and gastrointestinal stromal sarcoma (GIST) are excluded;
• Pregnant or lactating women, or women of childbearing potential who are not using contraceptive measures;
• Current severe, uncontrolled acute infection; or purulent or chronic infection with a persistent wound;
• Presence of a second primary tumor (excluding basal cell carcinoma of the skin);
• Participation in other drug clinical trials within 4 weeks;
• Presence of severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe valvular heart disease, and refractory hypertension;
• Suffering from uncontrolled neurological, psychiatric, or mental disorders, poor compliance, and inability to match the medication. Patients with uncontrolled primary brain tumors or central nervous system metastases and significant intracranial hypertension or neuropsychiatric symptoms are excluded.
• Evidence of a hereditary bleeding diathesis or coagulopathy.
• A history of severe allergic/anaphylactic reactions to humanized antibodies.
• Diagnosed with immunodeficiency or receiving systemic glucocorticoids or any other form of immunosuppressive therapy within 14 days prior to the first dose of the study drug. Physiological doses of glucocorticoids (≤10 mg/day of prednisone or equivalent) are permitted.
• Subjects with active, known, or suspected autoimmune diseases (e.g., interstitial pneumonitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, including but not limited to these diseases or syndromes) are excluded.

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead

Study Sites (1)

Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Hanzhong, Zhejiang, 310009, China

RECRUITING

MeSH Terms

Conditions

Sarcoma

Interventions

Doxorubicin; Ifosfamide

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Intervention Hierarchy (Ancestors)

Daunorubicin; Anthracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Aminoglycosides; Glycosides; Carbohydrates; Cyclophosphamide; Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Phosphoramides; Organophosphorus Compounds; Oxazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Central Study Contacts

Ying Dong

CONTACT

+8113666669105; dongying74@zju.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 24, 2025
• First Posted: November 24, 2025
• Study Start: September 30, 2024
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): June 1, 2027
• Last Updated: April 24, 2026

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: 2025.8.3-2026-9.1

Locations

CN (1)